Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid

Cullinan Therapeutics, Inc.

Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.
Monotherapy: 1 CR (mucoepidermoid parotid, 71 wks), 2 PRs (endometrial), 9 SD ≥18 wks; clinical benefit rate 41.4%.
Safety profile well tolerated; most TRAEs grade 1/2; no treatment-related deaths.
Based on data, expansion cohorts in NSCLC initiated; Phase 1 in relapsed/refractory multiple myeloma planned.
Data to be presented at ASCO 2024 on June 3; investor event June 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.